Journal
MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 487, Issue -, Pages 59-65Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2019.01.015
Keywords
Relaxin; Relaxin family peptides; Relaxin family peptidereceptor; Fibrosis; Nitric oxide; cGMP
Categories
Funding
- National Health & Medical Research Council (NHMRC) of Australia Senior Research Fellowship, Australia [GNT10417660]
- Novartis Pharma GmbH
- Bavarian State
- U.S. Department of Veterans Affairs Merit Review, USA [BX000849]
- [Sonderforschungsbereich SFB699]
Ask authors/readers for more resources
Fibrosis is associated with accumulation of excess fibrillar collagen, leading to tissue dysfunction. Numerous processes, including inflammation, myofibroblast activation, and endothelial-to-mesenchymal transition, play a role in the establishment and progression of fibrosis. Relaxin is a peptide hormone with well-known antifibrotic properties that result from its action on numerous cellular targets to reduce fibrosis. Relaxin activates multiple signal transduction pathways as a mechanism to suppress inflammation and myofibroblast activation in fibrosis. In this review, the general mechanisms underlying fibrotic diseases are described, along with the current state of knowledge regarding cellular targets of relaxin. Finally, an overview is presented summarizing the signaling pathways activated by relaxin and other relaxin family peptide receptor agonists to suppress fibrosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available